Kodak Expands Pharmaceuticals Portfolio with Four Regulated Products
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
phosphate buffered salinemedical
Phosphate buffered saline (PBS) is a simple, salt-based liquid that mimics the natural environment of cells and proteins in laboratory work, keeping them stable and at the right acidity during testing or production. Investors should care because PBS is a ubiquitous, low-cost consumable used in drug development, diagnostics, and biomanufacturing; supply, quality, or contamination issues can slow experiments, raise costs, or trigger regulatory scrutiny that affects timelines and revenues.
pbsmedical
A national drug reimbursement program that decides which prescription medicines are subsidized and at what price, similar to a large insurer choosing which treatments it will pay for and how much. For investors, listings, price decisions or changes under the scheme can sharply affect a drug maker’s sales, market access and revenue forecasts, so outcomes influence company valuations, clinical-commercial strategies and investment risk.
water for injectionmedical
Sterile, contaminant-free water made for mixing or delivering medicines directly into the body, often used to dilute drugs for injection or to rinse medical devices. Like a perfectly clean kitchen sink for a delicate recipe, it must meet strict production and safety rules because any impurity can stop a drug batch, trigger recalls or regulatory action, and therefore affect a drug maker’s ability to sell products and generate revenue.
wfimedical
WFI (Water for Injection) is highly purified water used to make sterile medicines, vaccines and injectable products; it is produced and tested to meet strict cleanliness and safety standards like a chef using distilled water for a delicate sauce. For investors, WFI matters because its availability and quality affect a drug maker’s ability to manufacture and sell injectable products safely—shortages, contamination or spending on WFI systems can change production capacity, costs and revenue risks.
cdmostechnical
Contract Development and Manufacturing Organizations (CDMOs) are independent companies that help drug and biologic developers by designing, testing, scaling up and producing medicines on a contract basis — think of them as a hired factory and research partner that turns a medical idea into a manufacturable product. They matter to investors because they provide steady, service-based revenue, spread development and production risk for drug makers, and their capacity, quality and pricing can directly affect the speed and cost of getting medicines to market.
cGMP-compliantregulatory
cGMP-compliant means a manufacturer follows the current Good Manufacturing Practices required by regulators to ensure products are made safely, consistently and with documented quality controls. For investors, cGMP compliance is like a certified clean kitchen and recipe book for a company’s manufacturing: it reduces the risk of product contamination, regulatory sanctions or recalls, supports reliable supply and can be essential for getting and keeping market approvals.
iso 13485regulatory
ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.
New U.S.-Manufactured PBS and WFI Offerings Deliver Reliable, High-Quality Supply for Labs, Biopharma Industry and CDMOs
ROCHESTER, N.Y.--(BUSINESS WIRE)--
Eastman Kodak Company (NYSE: KODK) today announced the expansion of its pharmaceuticals portfolio with four new regulated products: KODAK Phosphate Buffered Saline (PBS) 1X in low endotoxin and RNase/DNase/Protease-free formulations, and KODAK Water for Injection (WFI) in standard and RNase/DNase/Protease-free formulations. All are immediately available for order by U.S. research laboratories, biopharma developers, and contract development and manufacturing organizations (CDMOs).
The two new PBS formulations join a standard PBS 1X already shipping, while the WFI products represent the first offerings in that category. Customers gain the assurance of lot-traceable products built on Kodak’s rigorous quality processes, including a multi-step water purification system that supports consistently high purity, along with responsive and personalized service. Kodak is working on additional regulated pharmaceuticals for introduction in the future.
“The expansion of Kodak’s existing unregulated key starting materials business to include high-quality, reliable Class 1 regulated laboratory reagents is a milestone in our long-term plan,” said Jim Continenza, Kodak's Executive Chairman and CEO. “In addition to legendary Kodak quality, customers will benefit from the dependability of U.S. manufacturing and the ability to get exactly the formulation and volume they need.”
For decades, Kodak has manufactured unregulated key starting materials for premier U.S. and multinational CDMOs, and it has more than 1,400 customer-ready processes for specialty chemicals.
The new cGMP-compliant pharmaceuticals production facility in Rochester, N.Y. advances the organization’s sustainability commitment through energy-efficient lighting and custom process equipment to reduce greenhouse gas emissions, plus a water sterilization system that minimizes consumption and waste. Kodak is in the process of applying for ISO 13485 certification for medical device quality management systems.
To learn more and download complete product specifications, visit kodak.com/go/pharma.
About Kodak
Kodak (NYSE: KODK) is a leading global manufacturer focused on commercial print and advanced materials & chemicals. With 79,000 worldwide patents earned over 130 years of R&D, we believe in the power of technology and science to enhance what the world sees and creates. Our innovative, award-winning products, combined with our customer-first approach, make us the partner of choice for commercial printers worldwide. Kodak is committed to environmental stewardship, including industry leadership in developing sustainable solutions for print. For additional information on Kodak, visit us at Kodak.com or follow us on LinkedIn.
